Structure determination of amyloid oligomers, the pathogenic species in Alzheimeŕs disease using fast MAS NMR and microfluidics

Grant Agreement ID
H2020-EU.4. – Spreading excellence and widening participation
Call reference
H2020-WF-2018-2020 (Widening Fellowships)
Type of action
MSCA-IF-EF-ST – Standard EF
Implementation period
01.12.2021 – 30.11.2023
Project Leader
Alons Lends, PhD
€ 140 202,24 (EU contribution)

Alzheimer’s disease is a progressive neurodegenerative disorder affecting mainly the elderly population. It is characterised by the accumulation of amyloid beta and tau protein aggregates in neuronal cells. Despite their confirmed neurotoxicity, these protein oligomers have not been structurally characterised in detail. The scope of this project is to determine the structure and interaction of amyloid beta and tau oligomers using cutting-edge technologies.

Project results will provide fundamental knowledge in protein misfolding and aggregation in Alzheimer’s disease, opening new possibilities for the design of novel treatment strategies.